Protea Biosciences Group, Inc. (OTC: PRGB) is a provider of innovative bioanalytical solutions to the pharmaceutical and life science industries. The company applies its proprietary technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules, which are the byproducts of all living cells and life forms. Protea leads the field in mass spectrometry imaging services (MSI), providing a revolutionary capability that enables the identification and spatial display of biologically-active molecules in tissue and cells. MSI can be performed without sample preparation, labeling or antibody techniques, integrating for the first time direct identification of molecules with anatomic pathology. For more information, visit the company’s website at www.proteabio.com